BioWorld

July 27, 2007

Hydra Lands Potential $195M Deal With Pfizer On Pain Drugs

Hydra Biosciences Inc. licensed rights to its TRPV3 antagonist program to Pfizer Inc. in a deal valued at up to $195 million. (BioWorld Today) Read More

Exelixis Moving Forward On XL647 After GSK Declines

ATP Sense Channels Link Spinal Cord Injury, Stroke, Diabetes

Aspreva Restructures, Plans To Look Beyond CellCept

Revlimid Sales Drive Celgene's Second-Quarter Revenue Growth

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Businesswoman pressing dollar sign on touchscreen

JPM 2026: Year kicks off with biopharma Q4 revenue and guidance

BioWorld

It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...